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The potential role of the human immunodeficiency virus-1 (HIV-1) accessory protein Nef in
the pathogenesis of neuroAIDS is still poorly understood. Nef is a molecular adapter that
influences several cellular signal transduction events and membrane trafficking. In human
macrophages, Nef expression induces the production of extracellular factors (e.g. pro-in-
flammatory chemokines and cytokines) and the recruitment of T cells, thus favoring their
infection and its own transfer to uninfected cells via exosomes, cellular protrusions or cell-
to-cell contacts. Murine cells are normally not permissive for HIV-1 but, in transgenic mice,
Nef is a major disease determinant. Both in human and murine macrophages, myristoylated
Nef (myr+Nef) treatment has been shown to activate NF-κB, MAP kinases and interferon re-
sponsive factor 3 (IRF-3), thereby inducing tyrosine phosphorylation of signal transducers
and activator of transcription (STAT)-1, STAT-2 and STAT-3 through the production of
proinflammatory factors.
Methodology/Principal Findings
We report that treatment of BV-2 murine microglial cells with myr+Nef leads to STAT-1, -2
and -3 tyrosine phosphorylation and upregulates the expression of inducible nitric oxide
synthase (iNOS) with production of nitric oxide. We provide evidence that extracellular Nef
regulates iNOS expression through NF-κB activation and, at least in part, interferon-β
(IFNβ) release that acts in concert with Nef. All of these effects require both myristoylation
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and a highly conserved acidic cluster in the viral protein. Finally, we report that Nef induces
the release of neurotoxic factors in the supernatants of microglial cells.
Conclusions
These results suggest a potential role of extracellular Nef in promoting neuronal injury in the
murine model. They also indicate a possible interplay between Nef and host factors in the
pathogenesis of neuroAIDS through the production of reactive nitrogen species in microglial
cells.
Introduction
The term “neuroAIDS” encompasses different clinical syndromes including sensory neuropa-
thy, myelopathy, HIV-associated dementia (HAD), HIV-associated encephalitis (HIVE) and
cognitive/motor disorders. Despite their heterogeneity, these neurologic disorders are all char-
acterized by neuronal loss, due to damage of central and peripheral nervous system by HIV
(for review see [1]). Prior to highly active antiretroviral therapy (HAART) introduction, neuro-
logical disorders were the first manifestation of symptomatic HIV-1 infection, affecting rough-
ly 10/20% of patients and up to 60% of patients in the advanced stages of HIV-1/AIDS [2].
HAART has reduced the incidence of severe forms of AIDS-associated neurologic disorders
such as HIV-1-associated dementia (HAD) but, with longer life span, the prevalence of milder
forms of neurologic manifestations such as HIV-1-associated neurocognitive disorder
(HAND) appears to be increasing [3, 4].
Although substantial advances in deciphering the pathophysiological role of viral products
in the development of neuroAIDS have been achieved, two main aspects of HIV-associated
neuronal degeneration remain puzzling. First, neurological diseases are generally a later mani-
festation of HIV-1 infection and tend to progress in parallel with the degree of immunosup-
pression, while invasion of the nervous system may occur early upon viral infection, probably
concomitant with initial systemic infection [5]. Second, since the virus is unable to infect neu-
rons, the neuronal loss associated with neuroAIDS manifestations is not thought to be a direct
cytopathic effect of HIV-1 itself [6, 7]. Accumulating evidence suggests that over-activation of
the immune system, particularly of the macrophage subset, is the pathophysiological event
common to all of the neuroAIDS-associated syndromes [8]. Macrophage activation produces
pro-inflammatory cytokines, platelet activating factor (PAF), nitric oxide, and free oxygen radi-
cals that appear to contribute to the neuronal damage and dysfunction underlying the clinical
syndromes [7, 9–11]. Thus, neuroAIDS shares some similarities with other neurodegenerative
syndromes such as Alzheimer’s disease, Parkinson's disease and multiple sclerosis, in which ac-
tivated macrophages and microglial cells (i.e. the nervous system’s resident macrophages) act
as crucial disease determinants by sustaining an inflammatory microenvironment that ulti-
mately leads to nervous system damage.
Besides the production of inflammatory cytokines (interleukin, IL-1β, IL-6 and tumor ne-
crosis factor-α, TNFα) the macrophages and microglia inflammatory response is characterized
by the induction of oxygen and nitrogen reactive species (ROS and RNS, respectively), the lat-
ter following the activation of type 2 nitric oxide synthase (NOS2 or iNOS). In phagocytic cells,
inflammatory stimuli such as bacterial lipopolysaccharides (LPS), coupled to the production of
IFNγ by activated Th1 cells, trigger the NF-κB pathway and the expression of interferon re-
sponsive factor 1 (IRF-1) [12]. These two transcription factors cooperate by binding their
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specific target sequences located in the inos promoter region, thus inducing the synthesis of the
enzyme [13–15]. In contrast to neuronal and endothelial NOS (nNOS and eNOS, respectively),
iNOS is constitutively active once synthesized and acts in a Ca2+-independent manner [16,
17].
HIV-1 Nef is a small (MW 27–34 kDa) myristoylated, cytoplasmic, multifunctional viru-
lence factor acting as an adaptor molecule inside the cell. It is partially associated with the cell
membrane and plays multiple roles during HIV-1 replication [18–20]. Nef-defective viruses
lead to an attenuated clinical phenotype with reduced viral load in mouse models, monkeys,
and humans [21–25]. More recently, it has been shown that this viral protein can be transferred
to uninfected cells via cellular nanotubes, cell-to-cell contacts and release of exosomes. These
findings lead to the idea that Nef is able to regulate both the endocytotic and exocytotic cell
pathways thereby inducing specific effects also in non-infected cells [26].
In human monocyte-derived macrophages (MDMs), both Nef expression within the cell
and cell treatment with the recombinant protein induce a pro-inflammatory response charac-
terized by synthesis and release of specific cytokines and chemokines [27–32]. Nef-induced
pro-inflammatory state in macrophages is largely due to NF-κB activation [28, 32–34]. In addi-
tion, we reported that Nef treatment of MDMs activates IRF-3, the main transcriptional regula-
tor leading to the synthesis of IFNβ [32] and, ultimately, to the induction of IRF-1. Based on
these two premises, we hypothesized that Nef promotes synthesis and activation of iNOS in
microglial cells as a result of its pro-inflammatory properties. Consequently, iNOS-derived ni-
trogen reactive species might play a role in neuronal loss in a Nef-dependent manner. Due to
the lack of an available in vitro system based on human-derived microglial cells, we resorted to
a well characterized murine microglial cell line (i.e. BV-2, see [35]) and tested the above hy-
potheses by treating cells with myristoylated (myr+) Nef and by analyzing iNOS and RNS in-
duction, as well as the ability of RNS to induce neuronal death. Murine macrophages respond
to Nef treatment as human MDMs by activating IKKα and IKKβ, JNK, and p38 MAP kinases
[36]. Activation of the NF-κB pathway is mandatory for the tyrosine phosphorylation of signal
transducer and activator of transcription (STAT)-1, STAT-2, and STAT-3, which is induced
within 2 h in an autocrine and paracrine manner. These data confirmed that murine and
human macrophages respond similarly to myr+Nef treatment [36].
Although murine cells are not permissive for HIV-1 infection, several investigators have en-
gineered transgenic (Tg) mice to model HIV-1-induced diseases and overcome such restriction
[37–39]. The generation of Tg mice expressing selected HIV-1 genes revealed that Nef repre-
sents a major disease determinant and that the murine system is a suitable model to investigate
the mechanisms of Nef activity [37]. Nevertheless, in these studies the functions affected by
Nef in monocytes/macrophages have not been extensively investigated. To the best of our
knowledge, only two studies dealt with Nef expression in the brain of Tg mice: in the first one
Nef was expressed in oligodendrocytes [40], whereas in the second Nef was expressed in mac-
rophages/microglial cells but pro-inflammatory responses were not investigated [41].
In the present study, we describe that Nef treatment of murine microglial cells induces
iNOS expression that requires both NF-κB activation and ex novo synthesis of IRF-1, an event
dependent on IFNβ release. We also show that, similarly to other proinflammatory stimuli,
such as LPS, extracellular Nef cooperates with IFNβ to induce iNOS. The myristoylation site
and the acidic cluster of the viral protein are required for these effects. Finally, one or more fac-
tor(s), released in the supernatants of Nef-treated BV-2 microglial cells, induce neuronal death
in a Nω-Nitro-L-arginine methyl ester (L-NAME) sensitive way.
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Results
Extracellular Nef induces STATs phosphorylation, Iκ-B degradation and
IRF-1 expression in BV-2 microglial cells
Two main transcription factors are responsible for iNOS/NOS2 induction in murine as well as
human phagocytic cells, i.e. IRF-1 and NF-κB. Studies of the iNOS murine promoter revealed
the presence of two NF-κB and one IRF-1 binding sites [13–15]. We previously reported that
Nef activates the NF-κB signaling pathway, and synthesis of IRF-1 both in primary human
MDMs and murine macrophages [28–30, 32, 36]. Therefore, we assessed whether this was also
the case in microglial cells. First, we confirmed that myr+NefSF2 treatment induced tyrosine
phosphorylation of STAT-1, -2 and -3 in BV-2 cells in a time- and dose-dependent manner. In
particular, tyrosine phosphorylation signal increased starting from 2 h of cell treatment with
100 ng/ml of the viral protein and was clearly detectable after 5 h of treatment with 50 ng/ml
myr+NefSF2 (Fig 1A).
Subsequently, cells were challenged for different times (from 15 to 120 min) with myr+
NefSF2 and total cellular lysates were analyzed for the expression of I-κB-α, the alpha isoform
of the inhibitor of κB. As shown in Fig 1B, myr+NefSF2 treatment induced I-κB-α degradation
that became clearly evident after 60 to 75 minutes. At later time points, protein levels started to
recover, likely due to the neo-synthesis of I-κB which is itself encoded by a NF-κB regulated
gene [42, 43]. After 4/6 h of myr+NefSF2 treatment the expression of IRF-1, encoded by a
STAT-1 responsive gene, was clearly increased (Fig 1C). These results indicate that in murine
microglial cells Nef positively affects the two transcriptional factors involved in iNOS
regulation.
Nef treatment of murine microglial cells induces iNOS expression and
NO2
- production
Based on the above results, we asked whether extracellular Nef was able to regulate iNOS ex-
pression. First, BV-2 cells were exposed to myr+NefSF2 and iNOS mRNA levels were evaluated
by Real Time RT-PCR from 1 to 24 h post-treatment. As shown in Fig 2A, iNOS mRNA ex-
pression reached a peak at 6 h post-treatment, declined thereafter and increased again at 16
and 24 h, similarly to the kinetics of iNOS mRNA induction in cytokines-stimulated DLD-1
cells [44]. Induction of iNOS mRNA expression was also confirmed in primary murine micro-
glial cells (Fig 2B). To test whether iNOS expression and NO2
- production were both affected,
BV-2 cells were treated for 24 h with 100 to 500 ng/ml myr+NefSF2. iNOS protein levels were
measured in total cellular extract, whereas quantification of NO2
- released into the superna-
tants was performed using the Griess reagent. As depicted in Fig 2C and 2D, iNOS expression
and NO2
- release were induced in a dose-dependent manner by myr+Nef treatment of micro-
glial cells. The effect required the integrity of the protein, as heat-denaturated Nef barely in-
duced iNOS synthesis and NO2
- release. As a positive control, we evaluated NO2
- production
induced by LPS which is not sensitive to heat inactivation. To verify iNOS induction in a
human context, we polarized monocytes into M1 inflammatory macrophages by cultivating
them for 6 days in the presence of GM-CSF (Fig 2E). M1 macrophages were then treated with
myr+Nef in the presence of IFNγ for 24, 48 or 72 h. We were unable to detect nitrite accumula-
tion in the supernatants of Nef-treated M1 macrophages, due to the well known low NO2
-/
NO3
- ratio production in human cells [45], nevertheless we found that iNOS was slightly in-
duced in cells treated for 48 h with myr+Nef plus IFNγ compared to IFNγ treatment alone (Fig
2F and S1 File). Stimulation with LPS plus IFNγ, used as a positive control, induced iNOS at 24
and 48 h declining thereafter at 72 h (Fig 2F).
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iNOS upregulation induced by extracellular Nef requires both NF-κB and
IFNβ
As previously reported, iNOS expression is regulated by both NF-κB and IRF-1. To test wheth-
er the NF-κB pathway was involved in Nef-dependent iNOS induction, BV-2 cells were treated
with recombinant myr+NefSF2 in the presence of BMS-345541, a highly specific IKKα/IKKβ in-
hibitor. Pre-treatment with BMS-345541 at 5 μM concentration greatly reduced Nef-depen-
dent induction of iNOS mRNA levels (Fig 3A) and completely inhibited iNOS expression (Fig
3B). However, due to BMS-345541 cytotoxicity upon prolonged cell treatment, NO2
- produc-
tion was evaluated in supernatant of BV-2 cells treated with Nef for 24 h in the presence of
lower doses of the inhibitor (i.e. 1 and 2.5 μM). Nonetheless, these doses were still able to re-
duce NO2
- production in a dose-dependent manner (Fig 3C).
Fig 1. Nef treatment induces STATs tyrosine phosphorylation, I-B degradation and IRF-1 expression in BV-2 microglial cells. (A) BV-2 cells were left
untreated or incubated with 100 ng/ml wild type myristoylated Nef derived from HIV-1 SF2 strain (myr+NefSF2) for different times (left panel) or for 5 h with
different amounts of myr+NefSF2 (right panel). Total cellular extracts were analyzed byWestern Blot to evaluate STAT-1, -2 and -3 tyrosine phosphorylation or
protein expression using specific antibodies as described in materials and methods. (B, C) Cells were incubated for the indicated time with myr+NefSF2 (100
ng/ml) or, as a positive control, with LPS (500 ng/ml) for 30’ in (B) and 6 h in (C). Whole cell lysates were analyzed byWestern Blot for I-κB-α (B) or IRF-1 (C)
expression. β-tubulin expression was used as an internal loading control. Results reported in the figure are from four independent experiments.
doi:10.1371/journal.pone.0130189.g001
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In human MDMs we observed that Nef treatment induces both the synthesis and the release
of IFNβ followed by IRF-1 production [30, 32]. We also reported that Nef treatment induced
IRF-1 in RAW264.7, a murine macrophage cell line [36] and in BV-2 microglial cells (Fig 1C).
Based on these findings, we hypothesized that IFNβ blockade could affect iNOS upregulation.
BV-2 cells were incubated with myr+NefSF2 in presence of anti-IFNβ neutralizing antibodies
(NAb). As shown in Fig 4, anti-IFNβNAb started to inhibit the induction of iNOS mRNA at 8
h post-treatment (Fig 4A). This is in agreement with the kinetics of IRF-1 protein induction,
that follows Nef-induced degradation of Iκ-B (see Fig 1B). Consequently, iNOS expression was
also affected by anti-IFNβNAb starting from 6 h (Fig 4B, compare signals at 6 h in anti-IFNβ
treated and untreated cells). NO2
- detected in the culture supernatants appeared also reduced
after 24 h of treatment (Fig 4C). Taken together, these results demonstrated that Nef-induced
iNOS upregulation is primarily dependent on NF-κB signalling and, to a lesser extent, on IFNβ
production.
Extracellular Nef cooperates with IFNβ to induce iNOS expression
It is well recognized that stimuli that induce IRF-1 expression do not induce per se neither
iNOS expression nor NO2
- production, rather, they “prime” the cells to respond to NF-κB-acti-
vating stimuli, improving their effect on iNOS regulation. This is, paradigmatically, the case of
LPS and IFNγ combined treatment [46–48]. Therefore, we sought to test whether IFNβ has a
priming effect in promoting Nef-induced iNOS expression and function. The results shown in
Fig 5 demonstrate that combined treatment induced iNOS mRNA expression (Fig 5A), iNOS
protein levels (Fig 5B) and NO2
- production (Fig 5C) to a greater extent compared to what is
observed in cells exposed to myr+Nef alone.
Nef myristoylation and conserved acidic cluster are essential to induce
iNOS
We previously demonstrated that Nef-mediated interference with cell signalling in human and
murine macrophages treated with the viral protein required the integrity of both the N-termi-
nal myristoylation site and the acidic cluster (AC) which consists of four glutamates [28, 32,
36]. To determine whether these motifs are also required for iNOS induction, BV-2 cells were
treated with wild type myr+NefSF2, a mutant in the myristoylation site (i.e. G2A), two different
preparations of a myristoylation positive, AC-mutated viral protein (4EA’ and 4EA”), and a
Nef-deletion mutant lacking the N-terminal anchor domain (ΔN-term). The results shown in
Fig 6 indicate that all the mutants tested failed to induce iNOS mRNA expression (Fig 6A),
iNOS protein (Fig 6B), and NO2
- production alone or in IFNβ combined treatments (Fig 6C).
Conversely, other Nef mutants we tested retained their pro-inflammatory capabilities and
Fig 2. Nef treatment of microglial cells induces iNOS expression. BV-2 cells (A) or purified primary murine microglial cells (B) were treated for the
indicated time with myr+NefSF2 (100 ng/ml inA, 200 ng/ml in B, closed circles). Total cellular RNAs were isolated and real time RT-PCR analysis was
performed as reported in the materials and methods section. Results were expressed using the 2-ΔΔCT method using basal mRNA level in untreated cells
(Ctr, open circles) at T = 0 as a calibrator and GAPDH level as an internal loading control. (C, D) BV-2 cells were treated for 24 h with the indicated amounts of
myr+NefSF2, heat inactivated myr
+NefSF2 (Inactiv. recNef), LPS or heat treated LPS. Total cell lysates were analyzed byWestern Blot for iNOS (C, upper
panel) levels and, as internal loading control, β-Tubulin expression (C, lower panel). (D) NO2
- content in the supernatants was quantified using the Griess
colorimetric assay as reported in the materials and methods section. Dark gray bars: native myr+Nef or LPS. Light gray bars: heat pre-treated (Inactiv.)
myr+Nef or heat pre-treated LPS. Results from one of five independent experiments are shown. (E) Cell phenotyping by flow cytometry of humanmonocytes
and M1macrophages obtained as described in materials and methods. According to [77], human monocytes were CD14+/CD163+/CD86+ whereas M1
macrophages were CD14-/CD163-/CD86bright. (F) M1 humanmacrophages were left untreated or treated for 24, 48 and 72 h with IFNγ, 100 ng/ml wild type
myr+NefSF2 plus IFNγ, heat pre-treated myr
+NefSF2 and IFNγ or 100 ng/ml LPS plus IFNγ. Total cellular extracts were analyzed byWestern Blot to evaluate
iNOS expression using specific antibodies as described in materials and methods. β-tubulin expression as internal loading control. Blots are representative
of two independent experiments.
doi:10.1371/journal.pone.0130189.g002
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therefore their ability to induce iNOS expression and RNS production alone or in combined
treatment with IFNβ. We tested Nef mutants affecting functional motifs involved in the inter-
action and down-regulation of CD4 (CAWL), the interaction with SH3-containing proteins
(PxxPxP) or with proteins involved in endocytic pathways such as the V1H subunit of the vac-
uolar membrane ATPase or the adaptor protein complexes APs (DD and LL), as well as a loop
mutant lacking the C-terminal flexible loop (data not shown).These results assign the myris-
toylation site and the AC as essential structural motifs for Nef-mediated iNOS regulation.
Fig 3. Nef-dependent iNOS induction requires NF-κB. (A) BV-2 cells were pretreated for 1 h with BMS-345541 (5 μM) and then incubated for 2, 4 and 6 h
with myr+NefSF2 (100 ng/ml) in presence of BMS-345541. Total mRNAs were isolated and analyzed for iNOSmRNA expression as described in the materials
and methods section. Empty circles: untreated cells (Ctr); gray empty squares: BMS-345541; filled circles: recNefSF2; gray filled squares: BMS-345541 plus
recNefSF2. (B) Cells were stimulated as in (A) for 4, 6 and 8 h, then lysed and total cell lysates analyzed byWestern Blot for iNOS expression. β-Tubulin was
used as an internal loading control. (C) BV-2 cells were pre-treated with BMS-345541 (1 or 2.5 μM), then stimulated for 24 h with the indicated amount of
myristoylated recNefSF2 in presence of BMS-345541. Supernatants were collected and NO2
- content evaluated. Black bars: no inhibitor; dark gray bars:
BMS-345541 at 1 μM concentration; light gray bars: BMS-345541 at 2.5 μM concentration. Ctr: control cells. Data shown were from one of three
independent experiments.
doi:10.1371/journal.pone.0130189.g003
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Extracellular Nef induced the release of iNOS-dependent neurotoxic
factors in murine microglial cells
It is thought that both viral products and cellular derived factors are mainly responsible for the
neuronal loss observed in HAD [49]. To address whether Nef-dependent iNOS induction
could have neurotoxic effects, the supernatant of BV-2 cells exposed to myr+NefSF2 was collect-
ed and used to verify induction of cell death in NB41A3 murine neuroblastoma cell line. Super-
natant collected from microglial cells treated for 48 h with myr+Nef, or with LPS used as
positive control, induced cell death in NB41A3 cells (Fig 7C). This effect was completely abol-
ished by the pre-treatment of BV-2 microglial cells with the NOS inhibitor L-NAME (Fig 7C),
that prevented the Nef-dependent NO2
- production without affecting iNOS protein levels (Fig
7A and 7B). Treatment of NB41A3 cells for 24 h with myr+Nef, as well as LPS or L-NAME did
not induce any cytotoxic effects (Fig 7D). Again, supernatants collected from BV-2 cells treated
Fig 4. Nef-induced IFNβ production concurs to Nef-dependent iNOS induction. (A) BV-2 cells were treated for the indicated time with myr+NefSF2 (100
ng/ml) in the presence of anti-IFNβ neutralizing antibodies as described [36]. iNOSmRNA was analyzed as reported in materials and methods section. Dark
gray bars: 4 h treatment; light gray bars: 8 h treatment. (B) Cells were treated as in (A) for the indicated time and iNOS expression evaluated by Western Blot.
β-Tubulin expression was used as an internal loading control. (C) Cells were treated as in (A) for 24 h, supernatants were then collected and NO2
- content
measured using the Griess colorimetric assay.
doi:10.1371/journal.pone.0130189.g004
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with G2A or 4EA mutants did not cause cell death in neuroblastoma cells (Fig 7E), demonstrat-
ing that the myr+Nef neurotoxic effects also require these domains. All together, these results
show that Nef-stimulated microglial cells release NOS-dependent neurotoxic factor(s), whereas
Nef itself is not neurotoxic.
Fig 5. Nef synergizes with IFNβ in iNOS production. (A) BV-2 cells were treated for 6 h with myr+NefSF2 (100 ng/ml), IFNβ (200 IU/ml) or a combination of
both. iNOSmRNA was measured by real time RT-PCR as reported in the materials and methods section. (B) Cells were incubated for 24 h with the indicated
dose of myr+NefSF2 with or without IFNβ (50 IU/ml). Cells were also incubated with heat-inactivated recNefSF2 (inactiv. recNef, 500 ng/ml) or, as control, with
LPS or pre-heated LPS (500 ng/ml each). Total cellular lysates were analyzed byWestern Blot for iNOS expression. β-Tubulin expression was used as an
internal loading control. (C) Cells were treated like in (B) and NO2
- content in supernatants was measured using the Griess colorimetric assay. Empty
diamond: IFNβ; filled circles: myr+NefSF2; gray empty circles: heat-inactivated myr
+NefSF2; filled squares: recNefSF2 plus IFNβ; gray empty squares: heat-
inactivated myr+NefSF2 plus IFNβ.
doi:10.1371/journal.pone.0130189.g005
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Discussion
Compelling evidence indicates that the neurocognitive disorders associated with the develop-
ment and/or progression of AIDS are mainly due to the presence of infected macrophages/
microglial cells characterized by a pro-inflammatory M1 profile, in the central nervous system
(CNS). Indeed, neuroAIDS severity is directly correlated with the levels of pro-inflammatory
cytokines and chemokines, whereas no direct correlation with the viral load has been demon-
strated [50, 51]. Based on the theory of the “Trojan Horse” [52], HIV-1 is carried into the CNS
by infected macrophages, the only immune cells able to cross the Blood Brain Barrier; the infec-
tion is then spread to other susceptible CNS-resident target cells, either competent (i.e. micro-
glial cells) or defective (i.e. astrocytes) for HIV-1 replication [53]. The demonstrated presence
of macrophage-tropic strains into the CNS further supports this hypothesis [54, 55]. Even if to
the best of our knowledge, there is no evidence of Nef secretion from HIV-1 infected microglial
cells and/or astrocytes, it has been reported that HIV-1 infected cells release Nef into the
Fig 6. Nef myristoylation and the acidic cluster are essential to induce iNOS. BV-2 cells were left untreated or incubated with 100 ng/ml wild type (WT),
G2A, two different preparations of the EEEE!AAAAmutant (4EA’ and 4EA”) and ΔN-terminal deleted myr+NefSF2 proteins. (A) iNOSmRNA was measured
by real time RT-PCR using total RNA isolated from cells treated for 6 h. (B) Total cellular extracts obtained from cells treated for 24h were analyzed by
Western Blot using anti-iNOS antibodies, whereas β-tubulin expression levels were used as an internal loading control. (C) Supernatants collected from cells
treated as in (B) were measured for NO2
- content using the Griess colorimetric assay. One out of three independent experiments is shown.
doi:10.1371/journal.pone.0130189.g006
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extracellular microenviromment. Nef was detected in the medium from the MOLT-4 lympho-
cyte cell line transfected with a Nef-producing baculovirus vector and it was quantified in 32
patient serum samples [56]. This evidence suggests that infected cells would release Nef
through a non classical secretory pathway or after lysis. Then bystander cells like uninfected
microglial cells in the case of CNS, might internalize Nef via endocytosis, pinocytosis or other
unknow mechanisms, as we and others already reported for MDMs, dendritic and B cells [29,
57–61]. Once internalized, Nef could provoke the production of ROS and RNS as an integral
part of a pro-inflammatory response [62, 63].
Our previous studies demonstrated that Nef treatment of human MDMs induces the pro-
inflammatory response mainly through the activation of the NF-κB and IRF-3 transcription
factors that lead to synthesis and release of IL-1β, IL-6, TNFα, CCL3/macrophage inflammato-
ry protein 1a (MIP-1α), CCL4/MIP-1β and IFNβ [28, 29, 32]. Here we describe the ability of
Nef to influence also the production of nitrogen reactive species through the induction of type
2 NOS, in an in vitromurine model of microglial cells exposed to the recombinant protein. The
results reported in Fig 2 indicate a direct correlation between RNS production and Nef-induced
upregulation of iNOS, both at the mRNA and protein level. As already reported for other ca-
nonical inducers, such as LPS and IFNγ, also in the case of Nef, iNOS induction is achieved
through the activation of NF-κB and is reinforced by IRF-1 upregulation (Figs 3 and 4, respec-
tively). Even if we cannot formally exclude the hypothesis that a surface receptor for Nef may
activate a signalling cascade leading to iNOS induction, the observation that iNOS mRNA
upregulation was inhibited by both cytochalasin D and 5-(N,N-dimethyl)-amyloride, two com-
pounds which inhibit membrane ruffling and macropinocytosis [64, 65] argue against this hy-
pothesis (data not shown).
In line with previous results, we show that iNOS induction and RNS production require the
N-terminal myristoylation of Nef that influences Nef localization to the cellular membrane as
well as the integrity of its conserved acidic cluster (Fig 6), which was shown to be pivotal for
pro-inflammatory macrophage activation through the interaction with TNF receptor adapter
factor 2 [28]. Interestingly, protein alignment studies on neurotropic strain-derived Nef from
post-mortem biopsies revealed that some conserved amino acidic substitutions characterized
these viruses compared to patient-matched blood-derived samples [66]. Two of them are 71R/
K/T residue, in which the brain-derived viruses had arginine and lysine, whereas peripheral
blood-derived HIVs had a mixture of threonine, lysine and arginine and 83G/A residue, in
which brain-derived viruses displayed a glycine whereas blood-derived ones contained an ala-
nine [66]. These residues are located immediately downstream of the Nef acidic cluster and
they likely play a role in the stability and/or surface accessibility of this part of the protein that
might also mediate the “pro-inflammatory potential” of the acidic cluster.
Studies performed to identify the phenotype of infected macrophages in the CNS revealed
that both CD14+/CD45+ perivascular macrophages and multinucleated giant cells represent
the major source of infected cells in macaques [67], whereas CD14-/CD45- parenchymal
microglial cells do not express any viral factor. From this point of view, the capacity of Nef to
be transferred from infected cells to non-infected cells by exosomes and nanotubes or possibly
Fig 7. Nef-treated microglial cells release iNOS-dependent neurotoxic factors. (A) BV-2 cells were treated for 48 h with myr+NefSF2 (200 ng/ml) in the
presence (light gray bars) or absence (dark gray bars) of L-NAME at 10 μM concentration. Supernatants were collected and NO2
- content was measured
using the Griess colorimetric assay. (B) iNOS expression was evaluated on total cell lysates byWestern Blot using specific anti-iNOS antibodies (upper
panel) and anti-β-tubulin antibodies as an internal loading control (lower panel). (C) NB41A3 cells were incubated for 24 h with supernatants from (A). (D)
NB41A3 cells were treated for 24 h with myr+NefSF2 (200 ng/ml) or with LPS (100 ng/ml). Black line: No L-Name treatment; Gray line: L-Name (10 μM). (E)
NB41A3 cells were incubated for 24h with conditioned supernatants derived from untreated BV-2 cells or treated for 48 h with 200 ng/ml of wild type (WT),
G2A, 4EA’, 4EA” and ΔN-terminal deleted myr+NefSF2 proteins. In (C) to (E), cell viability was measured by flow cytometry using Propidium Iodide (PI) dye
exclusion and data were expressed as percentage of PI positive cells. One out of three independent experiments is shown.
doi:10.1371/journal.pone.0130189.g007
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via endocytosis as free protein (reviewed in [26]) should be emphasized. If this route of trans-
mission is active also in the CNS, Nef-dependent iNOS induction and production of RNS
might be achieved in non-infected microglial cells as well. As a consequence and regardless of
the nature of infected cells in the CNS, a deregulated proinflammatory response could be in-
duced, thereby promoting and/or accelerating the clinical onset of neurological disease [68].
Indeed, the production of matrix metalloproteinases MMP-2, -7, and -9, as well as IL-1, IL-6,
TNFα, nitric oxide (NO), L-cysteine, and Ntox further disseminate immune activation in non-
infected phagocytic cells.
Our results suggest a role of Nef in this macrophage- and/or microglial-based proinflamma-
tory environment, possibly contributing to the induction of neuronal death and neuronal
damage observed in the brain of AIDS patients [69]. Results obtained using the NB41A3 neu-
roblastoma cell line (Fig 7) demonstrated that the secreted factors induced by Nef in BV-2
cells, rather than Nef itself, are responsible for neuronal death assessed by PI uptake. These re-
sults are in conflict with reports indicating a direct neurotoxic activity of Nef due to its similari-
ty to scorpion peptides [70]. L-NAME-dependent inhibition of neuronal death suggests that
this phenomenon is dependent on NOS activity and NO production. Interestingly, NO2
-
,
provided to NB41A3 cells as NaNO2, was not toxic per se and supernatants collected from
microglia treated with myr+Nef for only 24 h were unable to induce NB41A3 cell death (data
not shown). The explanation of this observation is unknown at present, as the NO2
- content in
supernatants collected from BV-2 cells treated for 24 and 48 h with Nef did not differ signifi-
cantly (data not shown). It is conceivable that longer incubation times are needed to allow the
release of other products that in concert with NO2
- induce cell death in NB41A3 cells. In this
regard, it is interesting to note that both human and murine Nef-expressing astrocytes release
CXCL10/IP-10, a chemokine shown to induce neuronal death, and that its neurotoxicity is
more pronounced at 48 h than at 24 h after infection [71]. Further studies will be needed to
evaluate iNOS induction and production of neurotoxic factor in a bona-fide human microglial
cell system upon recombinant Nef treatment and/or Nef endogenous expression.
Materials and Methods
Cells cultures, recombinant Nef preparations and reagents
BV-2 cells, derived from primary murine microglial cells immortalized by transduction with v-
raf and v-myc expressing J2 retrovirus, were characterized before [72]. BV-2 cells were cultured
in Dulbecco’s modified essential medium (DMEM, Lonza, Milan, Italy) supplemented with
10% heat inactivated Fetal Calf Serum (iFCS, Lonza). NB41A3 neuroblastoma cell line [73, 74]
was a kind gift from Ada Maria Tata, Department of Cellular and Developmental Biology,
Sapienza University of Rome, Italy and was cultured in DMEM plus 10% iFCS. Primary mouse
microglia were purified as previously described [75]. In brief, mixed glial cultures were estab-
lished from the forebrain of 1-day old newborn CD1-Swiss mice. After 10 days in vitromicro-
glial cells were detached from the astroglial monolayer by gentle manual shaking of the culture
flasks; the supernatants were collected and centrifuged, and the cells were then reseeded on
plastic surfaces, at the density of 105 cells/cm2. After 1 h, the medium was replaced to remove
non-adherent cells and microglial cells were allowed to grow for additional 24 h before starting
experiments. The experimental procedures related to the use of newborn CD1 Swiss mice for
establishment of primary microglial cultures have been reviewed and approved by the Italian
Ministry of Health and the "Istituto Superiore di Sanitá" according to the italian law (Article 7,
Legislative Decree 116/92) and Council Directive 86/609/EC. All surgery was performed under
sodium pentobarbital anesthesia, and all efforts were made to minimize suffering.
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Monocytes were purified as in [28]. No ethical approval from our and University “La
Sapienza” ethics committees nor formal or verbal informed consent from blood donors were
necessary to use buffy coats as sources of primary monocytes. Blood samples are collected for
routine medical purpose and not specifically for this study. None of the authors collected the
blood samples nor had any direct contact with the donors, or had access to any identifying in-
formation. M1 polarization was performed as in [76] by culturing monocytes for 6 days in
RPMI, 10% FCSi supplemented with GM-CSF (Peprotech, Rocky Hill, NJ) at 50 ng/ml. Ac-
cording to [77], M1 phenotype was checked by flow cytometry using the following fluorch-
ome-conjugated antibodies: CD14-FITC (clone UCHM1, Becton Dickinson, Research Triangle
Park, NC), CD86-APC (clone IT2.2, BioLegend, San Diego, CA) and CD163-PE (clone GHI/
61, BioLegend). At least ten thousand events were recorded using a FACs ARIA II sorter (Bec-
ton Dickinson) and the obtained data were analyzed using Flowing software (v.2.5.1, Universi-
ty of Turku, Finland).
Wild-type (WT) myristoylated NefSF2, the mutant in the acidic cluster (E
66EEE69!AAAA),
the myristoylation deficient mutant (G2A) and the mutant lacking the first 44 amminoacids
(ΔN-Term), were co-expressed with a N-myristoyl-transferase expression vector in E.coli, in-
duced in presence of myristic acid and purified as C-terminal hexahistidine-tagged fusion pro-
teins as previously described [78]. WT as well as mutants preparations of the viral protein were
checked by SDS-PAGE and Coomassie staining after purification and titered by extinction co-
efficient measurement. Nef preparations were analyzed for the presence of endotoxin using the
chromogenic Limulus amebocyte lysate endpoint assay QCL-1000 and, if required, purified
using the EndoTrap endotoxin removal system (both from Lonza). Escherichia coli 0111:B4 li-
popolysaccharide (LPS), used as positive control, and L-NAME were purchased from Sigma-
Aldrich (Milan, Italy).
The highly specific IKKα/β inhibitor BMS-345541 [79, 80] was a kind gift from Dr. James
R. Burke, Department of Immunology, Inflammation and Pulmonary Drug Discovery, Bristol-
Myers Squibb Pharmaceutical Research Institute, Princeton, NJ.
Both murine IFNβ and anti-IFNβNAb (neutralizing titer 4x106 UI/ml) were a kind gift
from Dr. Paola Borghi, Department of Cell Biology and Neurosciences, Istituto Superiore di
Sanità, Rome, Italy.
Western blot assay
Assays were performed as previously described [28, 32]. In particular, cells were washed twice
with phosphate-buffered saline (PBS), pH 7.4, and lysed for 20 min on ice in Lysis Buffer:
20 mMHEPES, pH 7.9, 50 mM NaCl, 10 mM EDTA, 2 mM EGTA, 0.5% nonionic detergent
IGEPAL CA-630 (Sigma-Aldrich), protease and phosphatase inhibitors (COMPLETE and
phosphoSTOP, Roche, Milan, Italy). Whole-cell lysates were centrifuged at 6,000 g for 10 min
at 4°C, and the supernatants were frozen at 80°C. Protein concentration of cell extracts was de-
termined by the Lowry’s protein assay. Aliquots of cell extracts containing 20 to 50 μg of total
proteins were resolved on 7% or 10% sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis (SDS-PAGE) and transferred by electroblotting on nitrocellulose membranes (Sartorius,
Gottingen, Germany) overnight at 30 V with a Bio-Rad Trans-Blot apparatus. For the immu-
noassays, membranes were blocked in 3% bovine serum albumin (BSA) fraction V (Sigma-Al-
drich) in TTBS-EDTA (10 mM Tris, pH 7.4, 100 mMNaCl, 1 mM EDTA, 0.1% Tween 20) for
1 h at RT and then incubated overnight at +4°C with specific antibodies diluted in 1% BSA/
TTBS-EDTA. Antibodies were used as follows: rabbit polyclonal antibodies anti-iNOS and
anti-Iκ-B-α from Cell Signaling Technology (Beverly, MA); rabbit polyclonal antibodies anti-
IRF-1 (C-20) and rabbit polyclonal anti-human iNOS (N-20) from Santa Cruz Biotechnology
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(Santa Cruz, CA); mouse monoclonal anti β-tubulin from ICN Biomedicals (Costa Mesa, CA).
Immune complexes were detected with horseradish peroxidase conjugated goat anti-rabbit or
goat anti-mouse antiserum (Calbiochem/Merck, Milan, Italy), followed by enhanced chemilu-
minescence reaction (ECL; Amersham Pharmacia Biotech, Milan, Italy). To reprobe mem-
branes with antibodies having different specificities, nitrocellulose membranes were stripped
for 5 min at RT with Restore Western Blot Stripping Buffer (Pierce, Rockford, IL) and then ex-
tensively washed with TTBS/EDTA.
RNA isolation and real-time RT-PCR assay
Real-time reverse transcriptase-PCR assays were performed on total RNA as described else-
where [28]. Briefly, RNA was isolated using the RNeasy mini kit (Qiagen, Milan, Italy) accord-
ing to the manufacturer’s instructions. Five hundred nanograms of total RNA was reverse
transcribed using oligo(dT)12-18 (Pharmacia-Biotech) as a primer and 50 units of Moloney
murine leukemia virus reverse transcriptase enzyme (Gibco/Invitrogen, Milan, Italy). Quanti-
tative real-time PCR was then performed on reverse-transcribed iNOS mRNAs using syber-
green PCRmaster mix (Applied Biosysthems, Monza, Italy) according to manufacter’s instructions
and the following primers: iNOS Forward: 5’- GGCAGCCTGTGAGACCTTTG-3’; iNOS Re-
verse: 5’-GCATTGGAAGTGAAGCGTTTC-3’. The expression of GAPDH (glyceraldehyde-
3-phosphate dehydrogenase) was used to normalize the mRNAs levels (GAPDH Forward primer:
5’- TGAAGCAGGCATCTGAGGG-3’; GAPDH Reverse: 5’-CGAAGGTGGAAGAGTGGGAG-
3’). Basal mRNA level observed in untreated cells was chosen as a calibrator.
NO2
- production and quantification
NO2
- production was measured using the Griess colorimetric assay on supernatant of BV-2
microglial cells. Cells were treated in DMEM without red phenol plus 10% iFCS. Supernatants
were collected, clarified by centrifugation (3,500 g, 5’, 4°C) and stored at -80°C. Seventy
microlitres of supernatants were incubated in duplicate for 5’ at RT with 10 μl of 10 mM sulfa-
nilamide, 10 μl of 10 mMHCl and 10 μl of 10 mMNEDA (N-1-napthylethylenediamine dihy-
drochloride, all from Sigma Aldrich). Samples absorbance at 550 nm was evaluated with a
ELISA reader (EL800 Bio-Tek instruments, Inc., VT). Data were expressed as the percentage of
maximum NO2
- release obtained by treating cells with LPS 100 ng/ml.
Neuronal cell death assay
Supernatant collected from BV-2 cells treated with wt recNef (200 ng/ml) or with G2A and
4EA Nef mutants for 48 h in presence or not of L-NAME (10 μM) were centrifugated at 3,500
g, 5’, RT, filtered using a 0.22 μm filter and added to 50% confluent NB41A3 cells. Twenty four
hours later cells were collected and analyzed evaluating by cytofluorimetry the percentage of
propidium iodide (PI) positive cells. Ten thousand events were recorded using a DAKO Galaxy
flow cytometer (Dako, Glostrup, Denmark). Data analysis was performed using Flowing soft-
ware (v2.5.1, Turku Centre for Biotechnology, Finland).
Supporting Information
S1 File. Western Blot densitometric analysis of MDMs treated with Nef for 48 h. Panel of
Fig 1F corresponding to human MDMs treated for 48 h with IFNγ, 100 ng/ml wild type
myr+NefSF2 plus IFNγ, heat pre-treated myr
+NefSF2 and IFNγ or 100 ng/ml LPS plus IFNγ
was analyzed by densitometry using ImageJ software (v.1.48). Data were normalized using β-
Tubulin expression and expressed as fold of induction using the value of untreated MDMs
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